



Press Release |

IBA PLANS ACQUISITION OF CIS BIO INTERNATIONAL (CISBIO)

Embargo until 5:40 PM (Belgian time) – September 13, 2007

Louvain-la-Neuve, Belgium, September 13, 2007 – IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) announced today that it plans to increase its holdings in CIS bio International (CISBIO) to 100 percent. By way of background, IRE (Institut National des Radioéléments, based in Fleurus, Belgium) and IBA acquired 100 percent ownership of CISBIO from Schering AG through their RadioPharma Partners (RPP) consortium on May 5, 2006. As a result of this acquisition, IRE currently holds 80.1 percent of RPP and IBA, 19.9 percent.

CISBIO is a European and world leader in a biomedical technology, particularly with respect to in vitro medical diagnostics and radioactive marking of molecules used in nuclear medicine therapy and imaging. CISBIO is also in the international forefront of in vitro screening of new drugs, thanks to its HTRF® technology. Its products are used in several fundamental fields of medicine (oncology, cardiology, rheumatology, pneumology, and endocrinology). Headquartered in Saclay, near Paris, France, the company employs over 600 people and posted revenues of 120,4 million euros in 2006.

The terms of the CISBIO buyout are under negotiation between IBA and IRE and should be finalized in the first half of 2008, subject to the usual regulatory approvals. The price is expected to be on the order of 20 million euros, to be paid in both cash and shares in IBA S.A., in order to further strengthen the historic partnership between IBA and IRE, one of its founding shareholders. The cash payment will be used as a seed fund for projects useful to the joint development of IRE, CISBIO, and IBA.

According to Bernard Reculeau, Chief Executive Officer of CISBIO, “This step marks an important new chapter for our company, whose nuclear medicine business will be fully absorbed into IBA in order to create a radiopharmaceutical company that is strong in Europe and has the significant resources and assets needed to continue to provide the highest quality services to the medical community and patients. This will also make it possible to maximize the potential of CISBIO’s in vitro technology business.”

“CISBIO has significant complementarities with IBA,” said Pierre Mottet, Chief Executive Office of IBA. “We have great respect for the scientific and commercial achievements of CISBIO, which posted a large deficit in 2005 and has now reached the breakeven point. We believe that synergies with IBA will further strengthen CISBIO’s various operations and our two companies’ leadership position in nuclear medicine, particularly in Europe. Moreover, synergies with IRE will be maintained. With this acquisition, IBA becomes one of the most important players in the radiopharmaceutical industry in Europe and expects to increase its presence and improve the quality of its offering to customers in the most dynamic business areas—oncology, cardiology, and neurology—with new pharmaceutical products.”



Press Release |

ABOUT CISBIO

CISBIO is a developer and global maker of products and technologies for nuclear medicine, in vitro diagnostics, and the development of molecular screening tests to facilitate the discovery of new drugs. CISBIO is currently fully owned by RadioPharma Partners, a company organized under Belgian law held jointly by IRE (80.1 percent) and IBA (19.9 percent).

ABOUT IRE

Located in Fleurus, Belgium, IRE is a nonprofit foundation. Its mission is to promote the use of radioisotopes and to produce radioisotopes for nuclear medicine, as well as to engage in environmental protection and public health-related activities. IRE is a global leader in the production of fission-produced radioelements for medical applications (Mo/Tc 99m and I131, used in 80 percent of medical protocols) and exports most of its production.

ABOUT IBA

IBA is a developer of precision solutions for **cancer diagnosis and treatment**. It also offers sterilization and ionization solutions for optimal everyday hygiene and safety. Listed on the Euronext pan-European stock exchange, IBA is a member of the NextEconomy segment and is included in the BelMid index.

Website: www.iba-worldwide.com

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Tel.: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com